On July 14, Baxter International fell 5.14% in regular trading, trading at $21.40/share, with turnover of $19.65 million.

On the news front, Goldman Sachs raised its price target on Baxter International from $19 to $21 while maintaining a Neutral rating. However, the updated target remains near the current trading level, signaling limited upside potential. The consensus mean price target stands at $20.10 with an average Hold rating, reflecting broad institutional caution on the stock.

The broader Health Care Equipment sector experienced significant selling pressure on the same day. Among sector peers, Stryker fell 5.99%, Intuitive Surgical declined 4.0%, Medtronic dropped 4.0%, Boston Scientific lost 3.74%, and Abbott Laboratories fell 2.61%. The combination of sector-wide weakness and a cautious analyst stance weighed heavily on Baxter International shares.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)